Skip to main content
. 2017 May 15;7:94. doi: 10.3389/fonc.2017.00094

Figure 7.

Figure 7

Triple-negative breast cancer (TNBC) subtyping for CU_TNBC_002. We performed TNBC subtyping on the CU_TNBC_002 model and computed the correlation of this model at the pretreatment, sensitive on treatment and acquired resistance time points against the six TNBC subtypes. At the pretreatment and sensitive time points, we observed luminal androgen receptor (LAR) as the dominant subtype followed by BL2. However, at the acquired resistance time point, BL2 was the dominant subtype followed by LAR. This subtype switching suggests expansion of BL2 subtype at acquired resistance in this model.